An oral therapy that can allow children and adolescents with an aggressive form of brain cancer to be treated at home rather than in hospital has been recommended for use
AbbVie’s Aquipta has become the first once-daily oral therapy for both chronic and episodic migraine prevention to be recommended by NICE for NHS patients in England and W
NICE has launched a new consultation on the use of CYP2C19 genotype testing to guide treatment after a stroke or transient ischaemic attack (TIA) or ‘mini-stroke’.
Three digital health technologies (DHTs) used to support patients with psychosis can be used by the NHS while additional evidence of their benefits is gathered.
Dr Leeza Osipenko and colleagues analysed the quality of clinical evidence submitted by companies to NICE technology appraisals (TAs) over the last 20 years.
Up to 25,000 people with ulcerative colitis (UC) in England could be in line for treatment with Pfizer’s once-daily oral therapy Velsipity, after NICE recommended its use